Skip to main content

Table 2 Treatment-related adverse event: all events and grade ≥3 events

From: A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

  Any grade Grades 3–4
N (%) N (%)
Anemia 12 (60) 4 (20)
Neutropenia 11 (55) 10 (50)
Thrombocytopenia 16 (80) 12 (60)
Febrile neutropenia 2 (10) 0
Nausea and vomiting 10 (50) 0
Pyrexia 6 (30) 0
Transaminase increase 4 (20) 3 (15)